Companies
Beam Therapeutics
key ABE/CBE patents, BEAM-101 (sickle-cell disease).
- Country
- United States
FDA IND
Coverage
| CN | EU | US | |
|---|---|---|---|
| genome-engineering | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $500 million senior secured credit facility with Sixth Street, with a minimum of $200 million expected to be drawn. | investors.beamtx.com · sec.gov |
| Capacity | Automated process increased capacity by up to three-fold and reduced process duration. | investors.beamtx.com · sec.gov |
| Regulatory approval | BEAM-101 (risto-cel) has received U.S. FDA Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) Designation. | beamtx.com · investors.beamtx.com |
| Production site | 100,000 square foot cGMP facility in Research Triangle Park, North Carolina. | investors.beamtx.com · sec.gov |
| Headcount | 511 employees as of December 31, 2025. | longbridge.com · bccresearch.com · macrotrends.net |
| Revenue | $139.74 million for the fiscal year ended December 31, 2025. | longbridge.com · marketscreener.com |
Independent sources: bccresearch.com · beamtx.com · investors.beamtx.com · longbridge.com · macrotrends.net · marketscreener.com · sec.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Base editing | genome-engineering | Medium | → |
| Genome editing | genome-engineering | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.